Drug Profile
Taltobulin
Alternative Names: HTI-286; SPA-110; WAY-174286Latest Information Update: 05 Oct 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Class Antineoplastics; Oligopeptides
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
- 04 Jul 2003 Phase-I clinical trials in Cancer in USA (unspecified route)
- 04 Jul 2003 Wyeth has completed a phase I safety and pharmacokineic trial in patients with advanced malignant tumours